Urogen Pharma (NASDAQ:URGN) issued its quarterly earnings results on Tuesday. The company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.25), Fidelity Earnings reports. The company had revenue of $0.36 million for the quarter.
URGN opened at $41.17 on Thursday. Urogen Pharma has a 1-year low of $17.10 and a 1-year high of $69.57. The company has a market capitalization of $644.66 million, a price-to-earnings ratio of -19.24 and a beta of 2.11.
A number of brokerages recently weighed in on URGN. Cowen reaffirmed a “buy” rating on shares of Urogen Pharma in a research note on Tuesday, May 15th. Oppenheimer set a $75.00 target price on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Tuesday, May 22nd. ValuEngine raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research lowered shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $57.00.
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: Penny Stocks
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.